Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 4
1988 6
1989 6
1990 3
1991 9
1992 5
1993 5
1994 9
1995 8
1996 10
1997 13
1998 15
1999 15
2000 18
2001 14
2002 15
2003 18
2004 8
2005 11
2006 14
2007 17
2008 15
2009 13
2010 18
2011 12
2012 13
2013 24
2014 21
2015 23
2016 19
2017 27
2018 34
2019 25
2020 28
2021 24
2022 27
2023 21
2024 25
2025 37
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

565 results

Results by year

Filters applied: . Clear all
Page 1
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
Corpechot C, Carrat F, Gaouar F, Chau F, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Schramm C, Pares A, Olivas I, Eaton JE, Osman KT, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Dumortier J, Bruns T, Große K, Pageaux GP, Wetten A, Dyson J, Jones D, Chazouillères O, Hansen B, de Lédinghen V; Global & ERN Rare-Liver PBC Study Groups. Corpechot C, et al. J Hepatol. 2022 Dec;77(6):1545-1553. doi: 10.1016/j.jhep.2022.06.017. Epub 2022 Jun 28. J Hepatol. 2022. PMID: 35777587 Free article.
BACKGROUND & AIMS: Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) has been shown to predict outcomes of patients with primary biliary cholangitis (PBC) in small-size studies. ...Its value as a surrogate endp …
BACKGROUND & AIMS: Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) has been shown to pred …
A Current Understanding of Bile Acids in Chronic Liver Disease.
Farooqui N, Elhence A, Shalimar. Farooqui N, et al. J Clin Exp Hepatol. 2022 Jan-Feb;12(1):155-173. doi: 10.1016/j.jceh.2021.08.017. Epub 2021 Aug 23. J Clin Exp Hepatol. 2022. PMID: 35068796 Free PMC article. Review.
Chronic liver disease (CLD) is one of the leading causes of disability-adjusted life years in many countries. ...In the near future, further evidence in this area might help clinicians better detect and manage liver diseases....
Chronic liver disease (CLD) is one of the leading causes of disability-adjusted life years in many countries. ...In the near future, …
Cholestatic liver diseases: modern therapeutics.
McNally BB, Carey EJ. McNally BB, et al. Expert Rev Gastroenterol Hepatol. 2025 Apr;19(4):365-370. doi: 10.1080/17474124.2025.2473490. Epub 2025 Mar 2. Expert Rev Gastroenterol Hepatol. 2025. PMID: 40011221 Review.
INTRODUCTION: Cholestatic liver disease encompasses a broad group of disorders related to impaired normal bile formation, secretion, or excretion. ...AREAS COVERED: We focus on updates in the management of autoimmune cholestatic liver disease. The mainstay therapy i …
INTRODUCTION: Cholestatic liver disease encompasses a broad group of disorders related to impaired normal bile formation, secretion, …
Primary Biliary Cholangitis: A New Era.
Carey EJ, Levy C. Carey EJ, et al. Clin Liver Dis. 2018 Aug;22(3):xiii-xiv. doi: 10.1016/j.cld.2018.03.012. Epub 2018 Mar 31. Clin Liver Dis. 2018. PMID: 30259863 No abstract available.
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ. Harms MH, et al. J Hepatol. 2019 Aug;71(2):357-365. doi: 10.1016/j.jhep.2019.04.001. Epub 2019 Apr 11. J Hepatol. 2019. PMID: 30980847
BACKGROUND & AIMS: The clinical efficacy of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) remains subject to debate as definitive randomized controlled trials are lacking. ...LAY SUMMARY: In this international multicenter study of 3,902 …
BACKGROUND & AIMS: The clinical efficacy of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) remain …
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis.
Mayo MJ, Carey E, Smith HT, Mospan AR, McLaughlin M, Thompson A, Morris HL, Sandefur R, Kim WR, Bowlus C; TARGET-PBC Investigators; Levy C. Mayo MJ, et al. Dig Dis Sci. 2023 Mar;68(3):995-1005. doi: 10.1007/s10620-022-07581-x. Epub 2022 Jun 15. Dig Dis Sci. 2023. PMID: 35704252 Free PMC article.
BACKGROUND AND AIMS: Patients with primary biliary cholangitis (PBC) often suffer with pruritus. We describe the impact of pruritus on quality of life and how it is managed in a real-world cohort. ...Pruritus was reported in 170 patients (81%), with those rep …
BACKGROUND AND AIMS: Patients with primary biliary cholangitis (PBC) often suffer with pruritus. We describe the impact …
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.
Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, Kawashima M, Nishida N, Khor SS, Gervais O, Kawai Y, Nagasaki M, Tokunaga K, Tang R, Shi Y, Li Z, Juran BD, Atkinson EJ, Gerussi A, Carbone M, Asselta R, Cheung A, de Andrade M, Baras A, Horowitz J, Ferreira MAR, Sun D, Jones DE, Flack S, Spicer A, Mulcahy VL, Byan J, Han Y, Sandford RN, Lazaridis KN, Amos CI, Hirschfield GM, Seldin MF, Invernizzi P, Siminovitch KA, Ma X, Nakamura M, Mells GF; PBC Consortia; Canadian PBC Consortium; Chinese PBC Consortium; Italian PBC Study Group; Japan-PBC-GWAS Consortium; US PBC Consortium; UK-PBC Consortium. Cordell HJ, et al. J Hepatol. 2021 Sep;75(3):572-581. doi: 10.1016/j.jhep.2021.04.055. Epub 2021 May 23. J Hepatol. 2021. PMID: 34033851 Free PMC article.
BACKGROUNDS & AIMS: Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of the small intrahepatic bile ducts eventually leads to cirrhosis. ...CONCLUSIONS: This study has identified additional risk lo …
BACKGROUNDS & AIMS: Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruc …
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Corpechot C, Lemoinne S, Soret PA, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Pares A, Olivas I, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Dumortier J, Pageaux GP, de Lédinghen V, Chazouillères O, Carrat F; Global & ERN Rare-Liver PBC Study Groups. Corpechot C, et al. Hepatology. 2024 Jan 1;79(1):39-48. doi: 10.1097/HEP.0000000000000529. Epub 2023 Jul 3. Hepatology. 2024. PMID: 37399238
BACKGROUND AND AIMS: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended only wh …
BACKGROUND AND AIMS: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary …
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, Floreani A, Corpechot C, Mayo MJ, Battezzati PM, Parés A, Nevens F, Burroughs AK, Kowdley KV, Trivedi PJ, Kumagi T, Cheung A, Lleo A, Imam MH, Boonstra K, Cazzagon N, Franceschet I, Poupon R, Caballeria L, Pieri G, Kanwar PS, Lindor KD, Hansen BE; Global PBC Study Group. Lammers WJ, et al. Gastroenterology. 2014 Dec;147(6):1338-49.e5; quiz e15. doi: 10.1053/j.gastro.2014.08.029. Epub 2014 Aug 23. Gastroenterology. 2014. PMID: 25160979
BACKGROUND & AIMS: Noninvasive surrogate end points of long-term outcomes of patients with primary biliary cirrhosis (PBC) are needed to monitor disease progression and evaluate potential treatments. ...CONCLUSIONS: Levels of alkaline phosphatase and bili …
BACKGROUND & AIMS: Noninvasive surrogate end points of long-term outcomes of patients with primary biliary cirrhosis …
565 results